Simon Grant, CEO of Scibase, shares his knowledge and perspectives;
CEO Letter 9 – January 2022
On MDR, NMSC and US Strategy.
CEO Letter 8 – September 2020
Nevisense Go & MDR.
CEO Letter 7 – July 2020
Progress and Covid-19.
CEO Letter 6 – May 2020
US progress and Nevisense Go.
CEO Letter 5 – April 2019
Nevisense 3.0 and Skin Barrier application.
CEO-letter 4 – November 2017
Updated strategy and securing our long-term capital needs.
CEO-letter 3 – April 2017
Future trends and technologies.
CEO-letter 2 – January 2017
Nevisense View – a new product with great potential.
CEO-letter 1 – December 2016
Teledermoscopy – good for increased awareness and access but is it good enough as a diagnostic method?
